Medpace Holdings company profile

MEDP · NASDAQ · USD

Compare Medpace Holdings
$653.09Change from previous close: +0.75%Absolute change: +$4.89

Close · November 17, 2026

Company profile

Medpace Holdings has 6,600 employees and is headquartered in Cincinnati, United States.

Clinical trial work for drug and medical device developers is delivered across Australia, Africa, South America, Asia, Europe and North America. The company runs studies from Phase I through Phase IV for pharmaceutical, biotechnology and medical device sponsors active in a broad set of therapeutic areas. Its range covers study design, central laboratory coordination, regulatory submissions, post-marketing support, bio-analytical laboratory services, clinical pharmacology, imaging and electrocardiography reading for trials.

The company was founded in 1992 and is headquartered in Cincinnati, Ohio, with 6,600 employees. In the fiscal year ended December 2025, revenue reached 2,530.2 million US dollars, up 20.0% from the previous year, and net income was 451.1 million US dollars.

Company facts

Industry
Diagnostics & Research
Headquarters
5375 Medpace Way, 45227, Cincinnati
Employees
6,600
Chief executive
August Troendle
Founded
1992
Fiscal year
January - December
Listing
MEDP · NASDAQ
Currency
USD
ISIN
US58506Q1094

Medpace Holdings and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Medpace HoldingsMEDPUnited States$18.27B6,60021.4%36.3
RevvityRVTYUnited States$17.84B11,00016.3%70.5
Guardant HealthGHUnited States$20.52B2,490-39.4%—
Charles River Laboratories InternationalCRLUnited States$16.19B18,30014.3%367.4
ICON PublicICLRUnited States$14.58B40,2502.7%77.9
Quest DiagnosticsDGXUnited States$28.85B60,00014.9%26.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Medpace Holdings with its competitors